| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H26O3 |
| Molecular Weight | 326.4293 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC2
InChI
InChIKey=ROFBJLDRYQWJFI-WIRSXHRWSA-N
InChI=1S/C21H26O3/c1-3-20(23)24-14-5-7-15-13(12-14)4-6-17-16(15)10-11-21(2)18(17)8-9-19(21)22/h5,7,12,16-18H,3-4,6,8-11H2,1-2H3/t16-,17-,18+,21+/m1/s1
| Molecular Formula | C21H26O3 |
| Molecular Weight | 326.4293 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Estrone, the metabolite of estradiol, is used alone or in combination with other natural estrogens, in the form of ester (acetate, propionate~ or as hydrosoluble conjugate (sodium or piperazine sulphate) in the substitutive hormonal therapy (hypoestrogenic) and in the prevention of the bone loss in the cases of post-menopausal osteoporosis or in oophorectomized women.
Originator
Approval Year
PubMed
Sample Use Guides
OralMenopausal hormone replacement therapy, Prophylaxis of osteoporosisAdult: 1.4-2.8 mg daily in a cyclical or continuous regimen, usually given with estradiol and estriol. Cyclical progestogen should be given for 12-14 days of each cycle in women with intact uterus.
Route of Administration:
Oral